Chimeric antigen receptor polypeptides and methods of using same

Patent metadata

Field	Value
Publication number	US-12473344-B2
Application number	US-201917254618-A
Country	US
Kind code	B2
Filing date	Jul 3, 2019
Priority date	Jul 6, 2018
Publication date	Nov 18, 2025
Grant date	Nov 18, 2025

Abstract

Provided are polypeptides that include, from N-terminus to C-terminus, a chimeric antigen receptor (CAR), a protease, and a degron, where the polypeptide further includes a cleavage site for the protease disposed between the CAR and the degron. Also provided are cells that include such polypeptides (e.g., where the cells express the CAR on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the polypeptides, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for controlling the expression of a CAR on the surface of a cell, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable CAR cell-based therapy (e.g., a regulatable CAR T cell therapy) to an individual.

First claim

What is claimed is:

1 . A T cell expressing a polypeptide comprising from N-terminus to C-terminus:
a chimeric antigen receptor (CAR) comprising a single chain variable fragment (scFv); a hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease; and a degron comprising an amino acid sequence having 90% or greater identity to the amino acid sequence of SEQ ID NO:1, wherein the polypeptide further comprises a cleavage site for the protease disposed between the CAR and the protease.

2 . The T cell of claim 1 , wherein the polypeptide further comprises a spacer domain between the CAR and the cleavage site.

3 . The T cell of claim 2 , wherein the spacer domain decreases the response time of the polypeptide to an inhibitor of the protease.

4 . The T cell of claim 1 , wherein the scFv of the CAR specifically binds an antigen on the surface of a cancer cell.

5 . The T cell of claim 4 , wherein the antigen on the surface of the cancer cell is a tumor-associated antigen or a tumor-specific antigen.

6 . The T cell of claim 4 , wherein the antigen on the surface of the cancer cell is selected from the group consisting of: B7-H3 (CD276), CD19, GD2, CD22, and HER2.

7 . The T cell of claim 1 , wherein the protease comprises an amino acid sequence that is at least 80% identical to the amino acid sequence set forth in SEQ ID NO:2, which protease comprises an alanine at position 54, and wherein numbering is as in SEQ ID NO:2.

8 . The T cell of claim 1 , wherein the cleavage site for the protease is selected from the group consisting of: an NS4A/4B junction cleavage site, an NS3/NS4A junction cleavage site, an NS4A/NS4B junction cleavage site, an NS4B/NS5A junction cleavage site, and an NS5A/NS5B junction cleavage site.

9 . The T cell of claim 1 , wherein the degron comprises an amino acid sequence that is at least 95% identical, or 100% identical, to the amino acid sequence set forth in SEQ ID NO:1.

10 . The T cell of claim 1 , wherein the CAR comprises a signaling endodomain comprising 4-1BB and CD3 zeta.

Assignees

• Univ Leland Stanford Junior

Inventors

• Mackall Crystal
• Lin Michael
• Majzner Robbie
• Chung Hokyung
• Labanieh Louai

Classifications

• A61K40/421

  Immunoglobulin superfamily · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/48

  Blood cells, e.g. leukemia or lymphoma · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title